ArticleOsteoarthritis and cartilage open2025
Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study.
Article in Osteoarthritis and cartilage open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nomograms Based on X-Ray Radiomics for Predicting Pain Progression in Knee Osteoarthritis Using Data From the Foundation for the National Institutes of Health: Development and Validation Study.JMIR medical informatics · 2026Article
- Immunonutritional biomarkers in osteoarthritis: mechanistic insights and prognostic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study. Design: PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for knee OA. The primary outcome was medial or lateral joint space width loss (JSWL) ≥0.7 mm. Secondary outcomes included medial or lateral JSWL combined with symptomatic progression. Nine biochemical biomarkers identified in Phase I were included here. Logistic regression with elastic net selection examined associations between baseline biomarkers and outcomes over 12-36 months, separately for subgroups with available serum, urine, and both serum and urine biomarkers. Results: In total, the study included 827 participants across three RCTs, 159 (19 %) with JSWL≥0.7 mm. In 681 participants with both serum and urine biospecimens, the combination of serum hyaluronan (HA), urinary C2C-HUSA, body mass index (BMI), and Kellgren-Lawrence grade (KLG) yielded AUC 0.627 (95 % CI: 0.573, 0.681) for predicting JSWL≥0.7 mm, compared to AUC 0.612 (95 % CI: 0.557, 0.667) for BMI and KLG alone. Serum (HA) and urinary C2C-HUSA were consistently selected as predictors of disease progression in elastic net models across the subgroups. Conclusions: Biomarker associations were consistent with Phase I findings, but predictive performance remained modest. Future work in the FNIH OA Biomarkers consortium project will focus on evaluating short term changes in biomarkers to assess their potential for monitoring treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.